Pfizer Norvasc Advisory Committee Review Cancelled

FDA's Cardiovascular & Renal Drugs Advisory Committee was slated to review additional indications for amlodipine based on the ALLHAT study at an April 5 meeting. User fee deadline for the sNDAs is in June.